Advertisement
U.S. markets close in 6 hours 7 minutes

Clearmind Medicine Inc. (CMND)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.2683+0.0083 (+0.66%)
As of 09:46AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close1.2600
Open1.2600
Bid1.1600 x 100
Ask1.3200 x 100
Day's Range1.2600 - 1.2683
52 Week Range0.9210 - 24.6600
Volume2,556
Avg. Volume791,273
Market Cap4.137M
Beta (5Y Monthly)-1.69
PE Ratio (TTM)N/A
EPS (TTM)-31.3700
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for CMND

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Clearmind Medicine Inc.
    Daily – Vickers Top Insider Picks for 02/22/2023The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Rating
    Fair Value
    Economic Moat
    last yearArgus Research
View more
  • GlobeNewswire

    Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders

    Vancouver, Canada, April 10, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "company"), a clinical- stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced that it has filed a patent application with United States Patent and Trademark Office (USPTO) for the use of 3-methylmethcathinone (with the chemical name 2-(methylamino)-1-(3-methylphenyl)-1-p

  • GlobeNewswire

    Clearmind Medicine CEO Issues Letter to Shareholders

    Vancouver, Canada, April 09, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq:CMND), (FSE: CWY0) (“Clearmind” or the “company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today provided the following letter to shareholders from the Company’s CEO, Dr. Adi Zuloff-Shani: “In 2023, Clearmind made significant advances on its groundbreaking journey, propelling our flagship compou

  • GlobeNewswire

    Clearmind Medicine Announces International Patent Application for Preventing and Treating Depression

    Vancouver, Canada, March 27, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY) (“Clearmind” or the “company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced that it has submitted its tenth patent application under the international Patent Cooperation Treaty (“PCT”), as part of its ongoing collaboration with SciSparc Ltd. (Nasdaq: SPRC) (“SciSparc”), a specialty cli